While previous studies have not established a role for L-selectin in breast cancer, acute myeloid leukemia patients with elevated plasma L-selectin levels have poorer outcomes [46], and increased concentrations of L-selectin have also been observed in the serum of patients with metastatic versus nonmetastatic bladder cancer [47]. This evidence concerns the gene SELL and acute myeloid leukemia.